In patients with adenocarcinoma, adenosquamous and squamous-cell carcinoma, 41.8% (493/1178), 30.9% (21/68) and 6.6% (12/181) harbored EGFR-TKIs sensitive mutations (p < 0.001), respectively. Here, EGFR is linked to adenocarcinoma.